Heart disease seems impervious to cell therapy approaches. Is biomarker stratification the answer?

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

The dog-days of summer produced just a handful of mergers and acquisitions in the medtech sector and no blockbuster deals. However, several companies made smaller deals for innovative products in a range of sectors including IVDs, cardiovascular devices, and ophthalmology.

Intellia Therapeutics Inc. sold more shares in its initial public offering than originally expected and the CRISPR/Cas9 specialist did so at the top of its proposed price range, proving that investors remain excited about gene editing, but have less enthusiasm for other early-stage therapeutics firms.